<DOC>
	<DOCNO>NCT00604318</DOCNO>
	<brief_summary>To evaluate quality life patient 10 day pause thyroid medication ( Liothyronine ) compare treatment recombinant TSH ( Thyrogen ) radioiodine uptake treatment double-blinded , randomised cross-over design .</brief_summary>
	<brief_title>Quality Life , Recombinant TSH ( Thyrogen ) Thyroid Cancer</brief_title>
	<detailed_description>Patients thyroid follicular papillary cancer refer radioiodine treatment oncological department . The patient thyroidectomy treated Liothyronine treatment pause 10 day radioiodine . As routine patient re-evaluated iodine uptake 4 month later . The patient randomise either T3 pause relate first radioiodine treatment Thyrogen injection ( recombinant TSH ) relate second treatment/uptake - Thyrogen relate first treatment T3 pause related second treatment /uptake . All medication give 10 day period right radioiodine treatment/uptake deliver patient mark protocol number . In period T3 pause patient give placebo tablet injection saline ( instead Thyrogen ) treatment/uptake similar time give Thyrogen injection . A nurse otherwise involved study give injection . Patients evaluate VAS , SF-36 , Eortc QLC30 ( version 2.0 ) radioiodine treatment 3 week treatment .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<criteria>Follicular papillary thyroid cancer &lt; 18 &gt; 75 year old Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>quality life</keyword>
</DOC>